The potential acquisition of Syqe Medical by Phillip Morris represents a significant strategic move for the tobacco giant, signaling its entry into the flourishing marijuana industry. With an initial investment of $130 million to support Syqe’s FDA approval process, followed by a possible $650 million acquisition, this deal can potentially make Syqe one of the largest cannabis companies globally. Moreover, Syqe’s innovative inhaler, utilizing raw cannabis inflorescence, could secure FDA approval, positioning the company as a trailblazer in the medical cannabis sector.
Here's this week's Good Grades review of Eaton Botanicals new flavors: Gal Pal and Daily…
Here’s how you can support New York’s new legal cannabis dispensaries. The post New York’s…
The regulatory crackdown on intoxicating hemp products across multiple states underscores the complex interplay between…
During our conversation, my friend posited that cannabis could be a detriment to one's spiritual…
Florida Governor Ron DeSantis recently vetoed a bill that would have severely restricted the sale…
However, a glimmer of hope has emerged from an unlikely source: cannabis. Some individuals with…